GLUE
Monte Rosa Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.37B
P/E Ratio
—
EPS
$-0.46
Beta
1.64
52W High
$25.77
52W Low
$3.51
50-Day MA
$18.16
200-Day MA
$12.28
Dividend Yield
—
Profit Margin
-31.20%
Forward P/E
10.86
PEG Ratio
—
About Monte Rosa Therapeutics Inc
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new precision small molecule drugs that employ the body's natural mechanisms to selectively break down therapeutically relevant proteins. The company is headquartered in Boston, Massachusetts.
Fundamentals
| Revenue (TTM) | $123.67M |
| Gross Profit (TTM) | $-10.03M |
| EBITDA | $-45.85M |
| Operating Margin | -1788.00% |
| Return on Equity | -16.90% |
| Return on Assets | -7.64% |
| Revenue/Share (TTM) | $1.49 |
| Book Value | $3.56 |
| Price-to-Book | 5.87 |
| Price-to-Sales (TTM) | 11.08 |
| EV/Revenue | 8.32 |
| EV/EBITDA | 51.86 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -95.40% |
| Shares Outstanding | $80.02M |
| Float | $57.22M |
| % Insiders | 0.73% |
| % Institutions | 87.45% |
Analyst Ratings
Consensus ($32.17 target)
2
Strong Buy6
BuyData last updated: 4/8/2026